Navigation Links
Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia

First RNA Antagonist Medicine to Be Tested in Patients Reduces Severity of Adult Leukaemia

Copenhagen, 6th June 2007 - Santaris Pharma, the Danish biopharmaceutical company, announced today that SPC2996, the Company's new RNA Antagonist of Bcl-2, has shown early evidence of efficacy in an initial Phase I/II clinical study in Chronic Lymphocytic Leukaemia (CLL). The results of the study were reported this week at the 2007 Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois.

The clinical trial was conducted in patients with advanced CLL, the most common form of adult leukaemia, and involved 12 centres in France, Britain, Denmark, and the USA. Conclusions from the study were as follows.

*A reduction in the number of cancerous B-lymphocytes (white blood cells) and a beneficial effect on lymph nodes and overall tumour response was observed in patients given 6 repeated doses of drug at 4mg/kg/infusion over a two week period, with the effects on lymphocytes being seen within 24 hours of the first dose.

*A relationship between dose of SPC2996 and activity was observed in the study, with higher doses giving improved effects on lymphocyte counts, lymph nodes, time to progression and overall tumour response.

*SPC2996 treatment was associated with statistically significant reduction in mean Bcl-2 levels in white blood cells from CLL patients, supporting the intended mechanism of action of the drug.

Commenting on the results, Prof Bertrand Coiffier, from the Hospices Civils de Lyon, University of Lyon, France, the international coordinating investigator for the study, said:

"These results are early stage but promising. All patients came into this study with clinically progressing CLL. Despite this, patients receiving the drug at an effective level had rapid and sustained falls in circulating cancerous lymphocytes. There also appeared to be e
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:9/16/2014)... and BOSTON , September 16, ... Chief Scientific Officer, Fiona Marshall , will give a ... G protein-coupled receptors using StaR ®   ... Advances in Drug Discovery and Development " virtual symposium run ... Chemical Society. The virtual symposium is on Wednesday, 24 September ...
(Date:9/15/2014)... , Sept. 16, 2014  Bayer HealthCare ... Espoo, Finland , have begun ... with ODM-201, an investigational oral androgen receptor inhibitor ... ODM-201 in men with castration-resistant prostate cancer who ... no detectable metastases. The trial is designed to ...
(Date:9/15/2014)... 15, 2014 GenomeDx Biosciences today announced ... American Society for Radiation Oncology (ASTRO) Annual Meeting ... Classifier, a genomic test capable of predicting aggressiveness ... improve patient outcomes for prostate cancer patients following ... recently published study that demonstrates how Decipher test ...
Breaking Medicine Technology:Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 3
... SILVER SPRING, Md., July 1, 2011 The ... Neohaler (indacaterol inhalation powder) for the long term, ... people with chronic obstructive pulmonary disease (COPD) including ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) COPD is a ...
... DUBLIN, July 1, 2011 ,   ... SHPGY ), the global specialty,biopharmaceutical company, announces that it ... District of New Jersey against each,of Amneal Pharmaceuticals, LLC ... Shire,s VYVANSE,patents. The lawsuits were initiated in ...
Cached Medicine Technology:FDA Approves Arcapta Neohaler to Treat Chronic Obstructive Pulmonary Disease 2Shire Files Lawsuits Against Sandoz and Amneal for Infringement of VYVANSE® (lisdexamfetamine dimesylate) Patents 2
(Date:9/16/2014)... September 16, 2014 A recent ... used as a dermal filler, “Expression”, which has not ... on the market to be used as an intra-nasal ... FDA for use as a dermal filler. Because of ... off-label for wrinkle reduction, and patients have had bad ...
(Date:9/16/2014)... September 16, 2014 Dr. Eric Millstein ... of ACLsurgeryLA.com , a specialty website devoted to ... As an avid sports lover and athlete, Dr. Millstein ... and recovery from injuries to maintain active, healthy lifestyles. ... patients a resource dedicated specifically to ACL injuries ...
(Date:9/16/2014)... OXNARD, CA (PRWEB) September 16, 2014 ... Jivraj, founder of the Anacapa Dental Art Institute in ... Spectrum Day Vancouver conference this weekend. , Dr. Jivraj, ... about All-on-4™ dental implants in his presentation ... he will deliver at 12:40 p.m. Saturday, Sept. 20, ...
(Date:9/16/2014)... 2014 MEDICC Review today ... genetics in Cuba. Although the articles do not ... are intrinsically connected, since cancers begin with errors in ... full spectrum of cancer control, from primary prevention to ... topic of an exclusive interview with National Medical ...
(Date:9/16/2014)... NY (PRWEB) September 16, 2014 Registration ... Run For The Warriors®, a 10K, 5K, and 1-mile ... The race is sponsored by Local 338 RWDSU/UFCW, the ... will begin at the Town of Babylon Town Hall ... http://www.hopeforthewarriors.org/2014LIRun . The run is organized by Hope ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Non-approved Dermal Filler 2Health News:FDA Warns Against Non-approved Dermal Filler 3Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 2Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 4Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 5Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 2Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 3Health News:The Hope For The Warriors Long Island Run For The Warriors to Honor Wounded and Families of the Fallen 2
... of,Public Welfare said today it is working with ... an abandoned child in,Lansdowne, Delaware County., An ... noon today and said, "I left a baby ... without providing any other information. Local law,enforcement was ...
... and large numbers of men, are interested in having cosmetic ... Journal of Plastic and Reconstructive Surgery. , ... in cosmetic surgery, liposuction or both, and another 23 percent ... Among men, 23 percent said they would be interested in ...
... /PRNewswire/ - The IND proposes a randomized Phase,III ... Best Supportive,Care (BSC) versus BSC alone for the ... gastroesophageal junction and stomach who,have failed adjuvant or ... of the IND and will direct the clinical ...
... Oct. 26 In a statewide,effort to help ... violence shelters, the Michigan State Medical Society (MSMS),Foundation ... and,distribute personal care items in conjunction with the ... Day" on,Saturday, October 27., "The women and ...
... WHEATON, Ill., Oct. 26 The following is a,media ... Rehabilitation Hospital is the 2007 recipient of the,James Brady ... or organization,that goes above and beyond to improve lives ... goals of the Brain Injury Association of,Illinois., In ...
... UniCare announced today a policy to,make it easy for ... the prescription drugs they need. A one-time override ... up so,that UniCare policyholders in the affected counties can ... in place for,members living in Los Angeles, Orange, San ...
Cached Medicine News:Health News:Safe Haven Hotline Receives Report of Abandoned Baby in Lansdowne 2Health News:Huge numbers willing to go under knife to alter their appearance, study finds 2Health News:Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract 2Health News:Michigan State Medical Society Foundation 'Makes A Difference' by Assisting Those in Crisis Shelters 2Health News:Marianjoy Rehabilitation Hospital to Receive James Brady Award From Brain Injury Association of Illinois 2Health News:UniCare Announces Temporary Pharmacy Guidelines for Customers Affected by the California Wildfires 2
... Carl Zeiss has successfully advanced into the ... success of this instrument is by no ... and stylish design. Maximum ergonomic convenience is ... be used with a surgical microscope, allowing ...
... superior tissue excision with precision-matched, diamond-honed tips. ... pattern to capture loose bodies drawn into ... pin buffering system to minimize tip breakage ... pin buffering system applies increasing tension to ...
Leg holder for arthroscopy....
Osteoprep instruments provide an array of bone shaping devices especially suited for notchplasties....
Medicine Products: